BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/15/2023 2:14:31 AM | Browse: 196 | Download: 581
 |
Received |
|
2022-09-18 15:53 |
|
Peer-Review Started |
|
2022-09-18 15:56 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-02-04 06:37 |
|
Revised |
|
2023-02-11 05:14 |
|
Second Decision |
|
2023-02-24 03:24 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-02-28 00:46 |
|
Articles in Press |
|
2023-02-28 00:46 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2023-03-06 02:26 |
|
Typeset the Manuscript |
|
2023-03-07 04:54 |
|
Publish the Manuscript Online |
|
2023-03-15 02:14 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Review |
| Article Title |
Immunotherapy for advanced or recurrent hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ying-Zhe Luo and Hong Zhu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| The Key research projects of Science and Technology of Sichuan Province |
2022YFS0189 |
|
| Corresponding Author |
Hong Zhu, MD, PhD, Associate Professor, Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Wuhou District, Chengdu 610041, Sichuan Province, China. 441695131@qq.com |
| Key Words |
Recurrent hepatocellular carcinoma; Immunotherapy; Immune checkpoint inhibitor; Chimeric antigen receptor-engineered T cell; Oncolytic virus; Tumor vaccine |
| Core Tip |
The high recurrence rate of hepatocellular carcinoma (HCC) following radical treatment remains challenging; therefore, immune checkpoint inhibitors (ICIs) are increasingly being used to treat HCC. Herein, we discuss the ICIs in practice and those undergoing trials, and summarize the alternative strategies such as chimeric antigen receptor-engineered T cell therapy and tumor vaccines. Combination therapy is also a promising potential treatment option. We believe our study significantly contributes to the literature as it addresses the current state of immunotherapy against HCC and provides insights into the advantages and limitations, thereby facilitating future research. |
| Publish Date |
2023-03-15 02:14 |
| Citation |
Luo YZ, Zhu H. Immunotherapy for advanced or recurrent hepatocellular carcinoma. World J Gastrointest Oncol 2023;15(3): 405-424 |
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i3/405.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i3.405 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
